[1. Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, et al. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. Oncology. 2017;93(2):75-82. doi: 10.1159/000468522.10.1159/00046852228511189]Search in Google Scholar
[2. Le X, Hanna EY. Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined. Ann Transl Med. 2018;6(11):229.10.21037/atm.2018.05.10603600230023392]Search in Google Scholar
[3. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086-92. doi: 10.1200/JCO.2007.12.959310.1200/JCO.2007.12.9593512664418309943]Search in Google Scholar
[4. Park JC, Citrin DE, Agarwal PK, Apolo AB. Multi-modal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014;38(3):80-108. doi: 10.1016/j.currproblcancer.2014.06.00110.1016/j.currproblcancer.2014.06.001419016125087173]Search in Google Scholar
[5. Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Ein-horn LH, Albany C. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol. 2017;28(11):2670-2679. doi: 10.1093/annonc/mdx36010.1093/annonc/mdx360624672629045502]Search in Google Scholar
[6. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950-5.10.1056/NEJM1996122633526038960474]Search in Google Scholar
[7. Colombo N, Creutzberg C, Amant F, et al. ESMOESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2015;26(1):2-30. doi: 10.1097/IGC.000000000000060910.1097/IGC.0000000000000609467934426645990]Search in Google Scholar
[8. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53.DOI: 10.1056/NEJM19990415340150210.1056/NEJM19990415340150210202165]Search in Google Scholar
[9. Islam SS, Al-Sharif I, Sultan A, Al-Mazrou A, Remmal A, Aboussekhra A. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway. Mol Carcinog. 2018 Mar;57(3):333-346. doi: 10.1002/mc.22758.10.1002/mc.2275829073729]Search in Google Scholar
[10. Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635-49. doi: 10.3748/wjg.v20.i7.163510.3748/wjg.v20.i7.1635393096424587643]Search in Google Scholar
[11. Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016 Mar;44:42-50. doi: 10.1016/j.ctrv.2016.01.003.10.1016/j.ctrv.2016.01.00326866673]Search in Google Scholar
[12. Li H, Wang H, Deng K, Han W, Hong B, Lin W. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. Cancer Biomark. 2018 Dec 25. doi: 10.3233/CBM-181692.10.3233/CBM-18169230614795]Search in Google Scholar
[13. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 Oct 5; 0: 364–378. doi: 10.1016/j.ejphar.2014.07.02510.1016/j.ejphar.2014.07.025414668425058905]Search in Google Scholar
[14. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003 Jun;4(6):889-901. doi: 10.1517/14656566.4.6.88910.1517/14656566.4.6.88912783586]Search in Google Scholar
[15. Kobayashi R, Suzuki A, Matsuura K, Yamada N, Nakano M, Deguchi T, et al. Risk analysis for cisplatin-induced nephrotoxicity during first cycle of chemotherapy. Int J Clin Exp Med. 2016;9(2):3635–41.]Search in Google Scholar
[16. Tucker BM, Perazella MA. Medications. In: Lerma EV, Sparks MA, and Topf J. Nephrology Secrets. 4th ed. Philadelphia, PA:Elsevier;2018. p.78–83.10.1016/B978-0-323-47871-7.00019-8]Search in Google Scholar
[17. Perazella MA. Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents. Clin J Am Soc Nephrol. 2012 Oct;7(10):1713-21. doi: 10.2215/CJN.02780312.10.2215/CJN.0278031222879440]Search in Google Scholar
[18. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008 May;73(9):994-1007. doi: 10.1038/sj.ki.500278610.1038/sj.ki.500278618272962]Search in Google Scholar
[19. Dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012 Aug;86(8):1233-50. doi: 10.1007/s00204-012-0821-710.1007/s00204-012-0821-722382776]Search in Google Scholar
[20. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity.Toxins (Basel). 2010 Nov;2(11):2490-518. doi: 10.3390/toxins2112490.10.3390/toxins2112490315317422069563]Search in Google Scholar
[21. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin Nephrotoxicity: A Review. Am J Med Sci. 2007 Aug;334(2):115-24. doi: 10.1097/MAJ.0b013e31812dfe1e10.1097/MAJ.0b013e31812dfe1e17700201]Search in Google Scholar
[22. Bolisetty S, Traylor A, Joseph R, Zarjou A, Agarwal A. Proximal tubule-targeted heme oxygenase-1 in cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 2016 Mar 1; 310(5): F385–F394. doi:10.1152/ajprenal.00335.2015.10.1152/ajprenal.00335.2015486837026672618]Search in Google Scholar
[23. Ciarimboli G. Membrane Transporters as Mediators of Cisplatin Side Effects. Anticancer Res. 2014 Jan;34(1):547-50.]Search in Google Scholar
[24. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009 Mar;296(3):F505-11. doi: 10.1152/ajprenal.90545.2008.10.1152/ajprenal.90545.2008266019019144690]Search in Google Scholar
[25. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxi-city. Clin Pharmacol Ther. 2009 Oct;86(4):396-402. doi: 10.1038/clpt.2009.139.10.1038/clpt.2009.139274686619625999]Search in Google Scholar
[26. Ciarimboli G, Deuster D, Knief A, et al. Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions. Am J Pathol. 2010 Mar; 176(3): 1169–1180. doi: 10.2353/ajpath.2010.090610.10.2353/ajpath.2010.090610283214020110413]Search in Google Scholar
[27. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells.J Am Soc Nephrol. 2003 Jan;14(1):1-10.10.1097/01.ASN.0000042803.28024.92636114812506132]Search in Google Scholar
[28. Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010 Aug 8;2010. pii: 201367. doi: 10.4061/2010/201367.10.4061/2010/201367292960620811617]Search in Google Scholar
[29. Price PM, Safirstein RL, Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol. 2004 Feb;286(2):F378-84. doi: 10.1152/ajprenal.00192.200310.1152/ajprenal.00192.200312965891]Search in Google Scholar
[30. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest. 1998 Feb 15; 101(4): 777–782. doi: 10.1172/JCI1497.10.1172/JCI14975086259466972]Search in Google Scholar
[31. Zhou H, Kato A, Yasuda H, Miyaji T, Fujigaki Y, Yamamoto T, et al. The induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure. Toxicol Appl Pharmacol. 2004 Oct 15;200(2):111-20. doi: 10.1016/j.taap.2004.04.00310.1016/j.taap.2004.04.00315476864]Search in Google Scholar
[32. Price PM, Yu F, Kaldis P, et al. Dependence of Cisplatin-Induced Cell Death In Vitro and In Vivo on Cyclin-Dependent Kinase 2. J Am Soc Nephrol. 2006 Sep;17(9):2434-42. Epub 2006 Aug 16. doi: 10.1681/ASN.2006020162.10.1681/ASN.2006020162169829116914540]Search in Google Scholar
[33. Siddik Z. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003 Oct 20;22(47):7265-79. doi: 10.1038/sj.onc.1206933.10.1038/sj.onc.1206933]Search in Google Scholar
[34. Anderson B, Murray D. Clinically relevant resistance in cancer chemotherapy. Dordrecht : Kluwer Academic Publishers; 2002.10.1007/978-1-4615-1173-1]Search in Google Scholar
[35. Schieber M, Chandel NS. ROS Function in Redox Signaling and Oxidative Stress. Curr Biol. 2014 May 19;24(10):R453-62. doi: 10.1016/j.cub.2014.03.034.10.1016/j.cub.2014.03.034]Search in Google Scholar
[36. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998 Nov;54(5):1562-9. doi: 10.1046/j.1523-1755.1998.00161.x10.1046/j.1523-1755.1998.00161.x]Search in Google Scholar
[37. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke J. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain.J Pharmacol Exp Ther. 1997 Feb;280(2):638-49.]Search in Google Scholar
[38. Durak I, Ozbek H, Karaayvaz M, Oztürk HS. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity.Drug Chem Toxicol. 2002 Feb;25(1):1-8. doi:10.1081/DCT-10010846810.1081/DCT-100108468]Search in Google Scholar
[39. Appenroth D, Fröb S, Kersten L, Splinter FK, Winnefeld K. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol. 1997;71(11):677-83.10.1007/s002040050444]Search in Google Scholar
[40. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol. 2001 Dec;12(12):2683-90.10.1681/ASN.V12122683]Search in Google Scholar
[41. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol O. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res. 2003 Feb;47(2):149-56.10.1016/S1043-6618(02)00282-7]Search in Google Scholar
[42. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. doi: 10.1155/2014/967826.10.1155/2014/967826]Search in Google Scholar
[43. Lee RH, Song JM, Park MY, Kang SK, Kim YK, Jung JS. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol. 2001 Oct 15;62(8):1013-23.10.1016/S0006-2952(01)00748-1]Search in Google Scholar
[44. Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int. 2007 Jul;72(1):53-62. doi: 10.1038/sj.ki.500225610.1038/sj.ki.500225617410096]Search in Google Scholar
[45. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury.J Biol Chem. 2005 Sep 2;280(35):31230-9. doi: 10.1074/jbc.M50330520010.1074/jbc.M50330520015983031]Search in Google Scholar
[46. Yin X, Apostolov EO, Shah SV, Wang X, Bogdanov KV, Buzder T, et al. Induction of renal endonuclease G by cisplatin is reduced in DNase I-deficient mice. J Am Soc Nephrol. 2007 Sep;18(9):2544-53. doi: 10.1681/ASN.200608089610.1681/ASN.200608089617675668]Search in Google Scholar
[47. Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 2001 Nov;60(5):1726-36. doi: 10.1046/j.1523-1755.2001.00026.x10.1046/j.1523-1755.2001.00026.x11703590]Search in Google Scholar
[48. Cummings BS, McHowat J, Schnellmann RG. Role of an endoplasmic reticulum Ca2+-independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J Pharmacol Exp Ther. 2004 Mar;308(3):921-8. doi: 10.1124/jpet.103.06054110.1124/jpet.103.06054114634037]Search in Google Scholar
[49. Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol. 2005 Jul;16(7):1985-92. doi: 10.1681/ASN.200409076810.1681/ASN.200409076815901768]Search in Google Scholar
[50. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 2006 Mar;13(3):363-73. doi: 10.1038/sj.cdd.440181710.1038/sj.cdd.440181716397583]Search in Google Scholar
[51. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol. 2004 Sep;287(3):F543-9. doi: 10.1152/ajprenal.00112.200410.1152/ajprenal.00112.200415149969]Search in Google Scholar
[52. Clark JS, Faisal A, Baliga R, Nagamine Y, Arany I. Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells. Cancer Lett. 2010 Nov 28;297(2):165-70. doi: 10.1016/j.canlet.2010.05.00710.1016/j.canlet.2010.05.00720547441]Search in Google Scholar
[53. Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity.J Pharmacol Exp Ther. 2008 Nov;327(2):300-7. doi: 10.1124/jpet.108.13916210.1124/jpet.108.13916218682572]Search in Google Scholar
[54. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 2006 Jul 6;25(29):4056-66. doi: 10.1038/sj.onc.120944010.1038/sj.onc.120944016491117]Search in Google Scholar
[55. Han X, Yue J, Chesney RW. Functional TauT protects against acute kidney injury.J Am Soc Nephrol. 2009 Jun;20(6):1323-32. doi: 10.1681/ASN.200805046510.1681/ASN.2008050465268991019423693]Search in Google Scholar
[56. Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin XM, Dong Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 2008 Sep;74(5):631-40. doi: 10.1038/ki.2008.21410.1038/ki.2008.21418509315]Search in Google Scholar
[57. Kaushal GP, Shah SV. Autophagy in acute kidney injury.Kidney Int. 2016 Apr;89(4):779-91. doi: 10.1016/j.kint.2015.11.021.10.1016/j.kint.2015.11.021480175526924060]Search in Google Scholar
[58. Takahashi A, Kimura T, Takabatake Y, Namba T, Kaimori J, Kitamura H, et al. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol. 2012 Feb;180(2):517-25. doi: 10.1016/j.aj-path.2011.11.00110.1016/j.ajpath.2011.11.001]Search in Google Scholar
[59. Yang C, Kaushal V, Shah SV, Kaushal GP. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol. 2008 Apr;294(4):F777-87. doi: 10.1152/ajprenal.00590.200710.1152/ajprenal.00590.200718256309]Search in Google Scholar
[60. Jiang M, Wei Q, Dong G, Komatsu M, Su Y, Dong Z. Autophagy in proximal tubules protects against acute kidney injury. Kidney international. 2012;82(12):1271-1283. doi:10.1038/ki.2012.26110.1038/ki.2012.261349116722854643]Search in Google Scholar
[61. Inoue K, Kuwana H, Shimamura Y, Ogata K, Taniguchi Y, Kagawa T, et al. Cisplatin-induced macroautophagy occurs prior to apoptosis in proximal tubules in vivo. Clin Exp Nephrol. 2010 Apr;14(2):112-22. doi: 10.1007/s10157-009-0254-710.1007/s10157-009-0254-720013139]Search in Google Scholar
[62. Jiang M, Dong Z. Self-eating for death or survival during cisplatin nephrotoxicity?Clin Exp Nephrol. 2010 Oct;14(5):516-7. doi: 10.1007/s10157-010-0324-x.10.1007/s10157-010-0324-x20700622]Search in Google Scholar
[63. Anders HJ. Necroptosis in Acute Kidney Injury.Nephron. 2018;139(4):342-348. doi: 10.1159/000489940.10.1159/00048994029852497]Search in Google Scholar
[64. Tristao VR, Goncalves PF, Dalboni MA, Batista MC, Durao Mde S Jr., Monte JC. Nec-1 protects against nonapoptotic cell death in cisplatin-induced kidney injury. Ren Fail. 2012;34(3):373-7. doi: 10.3109/0886022X.2011.647343.10.3109/0886022X.2011.64734322260305]Search in Google Scholar
[65. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002 Sep;110(6):835-42. doi: 10.1172/JCI1560610.1172/JCI15606]Search in Google Scholar
[66. Liu M, Chien CC, Burne-Taney M, Molls RR, Racusen LC, Colvin RB, et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol. 2006 Mar;17(3):765-74. doi: 10.1681/ASN.200501010210.1681/ASN.2005010102]Search in Google Scholar
[67. Cenedeze MA, Gonçalves GM, Feitoza CQ, Wang PM, Damião MJ, Bertocchi AP, et al. The role of toll-like receptor 4 in cisplatin-induced renal injury. Transplant Proc. 2007 Mar;39(2):409-11. doi: 10.1016/j.transproceed.2007.01.03210.1016/j.transproceed.2007.01.032]Search in Google Scholar
[68. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity.J Am Soc Nephrol. 2008 May;19(5):923-32. doi: 10.1681/ASN.2007090982.10.1681/ASN.2007090982]Search in Google Scholar
[69. Chan AJ, Alikhan MA, Odobasic D, Gan PY, Khouri MB, Steinmetz OM, et al. Innate IL-17A-producing leukocytes promote acute kidney injury via inflammasome and Toll-like receptor activation.Am J Pathol. 2014 May;184(5):1411-8. doi: 10.1016/j.aj-path.2014.01.023.10.1016/j.ajpath.2014.01.023]Search in Google Scholar
[70. Dong Z, Atherton SS. Tumor necrosis factor-alpha in cisplatin nephrotoxicity: a homebred foe? Kidney Int. 2007 Jul;72(1):5-7. doi: 10.1038/sj.ki.500232010.1038/sj.ki.5002320]Search in Google Scholar
[71. Locksley RM, Killeen N, Lenardo MJ.The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001 Feb 23;104(4):487-501. doi: 10.1016/S0092-8674(01)00237-910.1016/S0092-8674(01)00237-9]Search in Google Scholar
[72. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol. 2003 Oct;285(4):F610-8. doi: 10.1152/ajprenal.00101.200310.1152/ajprenal.00101.200312865254]Search in Google Scholar
[73. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005 Jul;289(1):F166-74. doi: 10.1152/ajprenal.00401.200410.1152/ajprenal.00401.200415701814]Search in Google Scholar
[74. Ramesh G, Reeves WB. Cisplatin increases TNF-alpha mRNA stability in kidney proximal tubule cells. Ren Fail. 2006;28(7):583-92. doi: 10.1080/0886022060084383910.1080/0886022060084383917050242]Search in Google Scholar
[75. Ramesh G, Zhang B, Uematsu S, Akira S, Reeves WB. Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am J Physiol Renal Physiol. 2007 Jul;293(1):F325-32. doi: 10.1152/ajprenal.00158.200710.1152/ajprenal.00158.200717494092]Search in Google Scholar
[76. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 2007 Jul;72(1):37-44. doi: 10.1038/sj.ki.500224210.1038/sj.ki.500224217396112]Search in Google Scholar
[77. Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 1999 Sep;56(3):922-31. doi: 10.1046/j.1523-1755.1999.00629.x10.1046/j.1523-1755.1999.00629.x10469360]Search in Google Scholar
[78. Tadagavadi RK, Reeves WB. Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells. J Immunol. 2010 Oct 15;185(8):4904-11. doi: 10.4049/jimmunol.100038310.4049/jimmunol.1000383316990820844196]Search in Google Scholar
[79. Akcay A, Nguyen Q, He Z, et al. IL-33 Exacerbates Acute Kidney Injury.J Am Soc Nephrol. 2011 Nov; 22(11): 2057–2067. doi: 10.1681/ASN.201009101110.1681/ASN.2010091011327999821949094]Search in Google Scholar
[80. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001 Dec;60(6):2118-28. doi: 10.1046/j.1523-1755.2001.00043.x10.1046/j.1523-1755.2001.00043.x11737586]Search in Google Scholar
[81. Kim H, Lee H, Lee G, Jang H, Kim SS, Yoon H, et al. Phospholipase A2 inhibits cisplatin-induced acute kidney injury by modulating regulatory T cells by the CD206 mannose receptor. Kidney Int. 2015 Sep;88(3):550-9. doi: 10.1038/ki.2015.147.10.1038/ki.2015.14725993317]Search in Google Scholar
[82. Summers SA, Chan J, Gan P-Y, et al. Mast Cells Mediate Acute Kidney Injury through the Production of TNF. J Am Soc Nephrol. 2011 Dec; 22(12): 2226–2236. doi: 10.1681/ASN.2011020182.10.1681/ASN.2011020182327993422021718]Search in Google Scholar
[83. Wang Y, Thorlacius H. Mast cell-derived tumour necrosis factor-alpha mediates macrophage inflammatory protein-2-induced recruitment of neutrophils in mice. Br J Pharmacol. 2005 Aug;145(8):1062-8. doi: 10.1038/sj.bjp.070627410.1038/sj.bjp.0706274157622415937521]Search in Google Scholar
[84. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, et al. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 2007 Jul;322(1):8-15. doi: 10.1124/jpet.107.11979210.1124/jpet.107.11979217400889]Search in Google Scholar
[85. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis.Kidney Int. 2004 Dec;66(6):2202-13. doi: 10.1111/j.1523-1755.2004.66010.x10.1111/j.1523-1755.2004.66010.x15569309]Search in Google Scholar
[86. Tadagavadi R, Reeves WB. Neutrophils in cisplatin AKI-mediator or marker? Kidney Int. 2017 Jul;92(1):11-13. doi: 10.1016/j.kint.2017.03.023.10.1016/j.kint.2017.03.02328646989]Search in Google Scholar
[87. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha.Kidney Int. 2004 Feb;65(2):490-9. doi: 10.1111/j.1523-1755.2004.00413.x10.1111/j.1523-1755.2004.00413.x14717919]Search in Google Scholar
[88. Tadagavadi RK, Gao G, Wang WW, Gonzalez MR, Reeves WB. Dendritic Cell Protection from Cisplatin Nephrotoxicity Is Independent of Neutrophils. Toxins (Basel). 2015 Aug 19;7(8):3245-56. doi: 10.3390/toxins7083245.10.3390/toxins7083245454974826295408]Search in Google Scholar
[89. Tarang S, Sodhi A, Chauhan P. Differential expression of Toll-like receptors in murine peritoneal macrophages in vitro on treatment with cisplatin.Int Immunol. 2007 May;19(5):635-43. doi: 10.1093/intimm/dxm02910.1093/intimm/dxm02917446211]Search in Google Scholar
[90. Inoue T. M1 macrophage triggered by Mincle leads to a deterioration of acute kidney injury. Kidney Int. 2017 Mar;91(3):526-529. doi: 10.1016/j.kint.2016.11.026.10.1016/j.kint.2016.11.02628202166]Search in Google Scholar
[91. Li J, Tang Y, Tang PMK, Lv J, Huang XR, Carlsson-Skwirut C, et al. Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice. Mol Ther. 2018 Oct 3;26(10):2523-2532. doi: 10.1016/j.ymthe.2018.07.014.10.1016/j.ymthe.2018.07.014617107530077612]Search in Google Scholar
[92. Jang HR, Rabb H. Immune cells in experimental acute kidney injury. Nat Rev Nephrol. 2015 Feb;11(2):88-101. doi: 10.1038/nrneph.2014.180.10.1038/nrneph.2014.18025331787]Search in Google Scholar
[93. Nozaki Y, Nikolic-Paterson DJ, Yagita H, Akiba H, Holdsworth SR, Kitching AR. Tim-1 promotes cisplatin nephrotoxicity.Am J Physiol Renal Physiol. 2011 Nov;301(5):F1098-104. doi: 10.1152/ajprenal.00193.2011.10.1152/ajprenal.00193.201121835770]Search in Google Scholar
[94. Tadagavadi RK, Reeves WB. Renal Dendritic Cells Ameliorate Nephrotoxic Acute Kidney Injury. J Am Soc Nephrol. 2010 Jan; 21(1): 53–63. doi: 10.1681/ASN.200904040710.1681/ASN.2009040407279927219875815]Search in Google Scholar
[95. Okusa MD, Li L. Dendritic Cells in Acute Kidney Injury: Cues from the Microenvironment. Trans Am Clin Climatol Assoc. 2012; 123: 54–63.]Search in Google Scholar
[96. Lee H, Nho D, Chung HS, Lee H, Shin MK, Kim SH, et al. CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. Kidney Int. 2010 Dec;78(11):1100-9. doi: 10.1038/ki.2010.139.10.1038/ki.2010.13920463654]Search in Google Scholar
[97. Portilla D, Safar AM, Shannon MI, et al. Cisplatin nephrotoxicity. https://www.uptodate.com/cisplatin_nephrotoxicity. Date last accessed: January 5, 2019. Date last updated: Feb 14, 2018.]Search in Google Scholar
[98. Glezerman IG, Jaimes EA. Chapter 11. Chemotherapy and Kidney Injury. Αmerican Society of Nephrology Onco-Nephrology Curriculum [Internet]. 2016 [cited 2019 Jan 05]. p. 1–10. Available from: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter11.pdf]Search in Google Scholar
[99. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999 Feb;25(1):47-58. doi: 10.1053/ctrv.1999.009710.1053/ctrv.1999.009710212589]Search in Google Scholar
[100. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988 Jan;108(1):21-5.10.7326/0003-4819-108-1-213337511]Search in Google Scholar
[101. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A. Cisplatin-induced renal salt wasting syndrome. South Med J. 2010 Aug;103(8):793-9. doi: 10.1097/SMJ.0b013e3181e63682.10.1097/SMJ.0b013e3181e6368220622742]Search in Google Scholar
[102. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM. 2014 Apr;107(4):261-9. doi: 10.1093/qjmed/hct258.10.1093/qjmed/hct25824368854]Search in Google Scholar
[103. Sirac C, Bridoux F, Essig M, Devuyst O, Touchard G, Cogné M. Toward understanding renal Fanconi syndrome: step by step advances through experimental models. Contrib Nephrol. 2011;169:247-61. doi: 10.1159/00031396210.1159/00031396221252524]Search in Google Scholar
[104. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995 Apr;95(4):1650-9. doi: 10.1172/JCI11784010.1172/JCI1178402956697706473]Search in Google Scholar